Daiichi Sankyo enrolls first patients in mirogabalin clinical trials

Daiichi Sankyo Co., Ltd., said Wednesday that it has enrolled the first patients in its initial large-scale and multinational clinical studies program to assess the efficiency and safety of mirogabalin, an investigational treatment for diabetic peripheral neuropathic (DPNP) and postherpetic neuralgia (PHN).

The Phase 3 clinical program throughout Asia includes the NEUCOURSE study and the REDUCER study, which are assessment studies of investigational mirogabalin in DPNP and PHN patients. It also contains the phase 3 ongoing global ALDAY clinical program evaluating mirogabalin for the treatment of pain linked with fibromyalgia.

“Pain associated with the neurologic conditions of diabetic peripheral neuropathic pain, postherpetic neuralgia and fibromyalgia can be debilitating,” Dr. Lesley Arnold, professor of psychiatry and behavioral neuroscience and director of the Women’s Health Research Program at the University of Cincinnati, as well as lead investigator of the ALDAY drug program, said.

“Daiichi Sankyo is committed to identifying and studying new medicines that could help improve the management of chronic pain for people with diabetic peripheral neuropathy, postherpetic neuralgia and pain associated with fibromyalgia,” Mahmoud Ghazzi, executive vice president and global head of development for Daiichi Sankyo, said.

Want to get notified whenever we write about Daiichi Sankyo, Inc. ?
Next time we write about Daiichi Sankyo, Inc., we'll email you a link to the story. You may edit your settings or unsubscribe at any time.
Organizations in this story

Daiichi Sankyo, Inc. 2 Hilton Ct Parsippan, NJ 07054